Tag: CD22-targeted therapy

Home / CD22-targeted therapy

Categories

Inotuzumab ozogamicin is approved by the USFDA for pediatric patients with acute lymphoblastic leukemia

6th March 2024: Inotuzumab ozogamicin (Besponsa, Pfizer) has been granted approval by the Food and Drug Administration for the treatment of relapsed or refractory CD22-positive B-cell precursor acute...
cd22-targeted-therapy

Scan the code